Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

← catalyst calendar

NCT06398080 · readout in 502 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase
Status
Withdrawn
Study type
Observational
Enrollment
0actual

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Sponsor Decision

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-12-12estimatedWhen the study began enrolling
Primary completion2028-01-03estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2029-01-03estimatedThe whole study's end, after follow-up
First posted2024-05-03actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2024-11-25actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)
  • Wet Age-related Macular Degeneration (AMD)
  • Diabetic Macular Edema (DME)
  • Visual Impairment

Intervention

  • Drug: aflibercept 8 mg — also filed as EYLEA® HD

Primary outcomes

what the primary-completion date above is the date OF
Mean prior treatment interval during the one-year period before study enrollment compared to the last assigned treatment interval during the study
measured Up to 12 Months
Change in visual acuity (VA) (Early Treatment Diabetic Retinopathy study [ETDRS]) letters)
measured Baseline up to 12 Months

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed